CME Information

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Identify appropriate patients for primary cancer-associated thrombosis (CAT) prophylaxis
• Establish plan for VTE prophylaxis in patients with cancer

FACULTY
James D. Douketis, MD, FRCPC, FACP, FCCP, FCAHS
Professor, Department of Medicine
St. Joseph’s Healthcare and McMaster University
Hamilton, Canada

PLANNERS
Jean M. Connors, MD
Hematology Division
Brigham and Women’s Hospital/Dana Farber Cancer Institute
Associate Professor Harvard Medical School
Boston, Massachusetts

James D. Douketis, MD, FRCPC, FACP, FCCP, FCAHS
Professor, Department of Medicine
St. Joseph’s Healthcare and McMaster University
Hamilton, Canada

Dominique Farge-Bancel, MD
Professor of Internal Medicine
Hôpital Saint-Louis, University of Paris, France
McGill University, Montreal, Canada

TARGET AUDIENCE
This activity is intended for hematologists/oncologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology pharmacists, and other healthcare professionals who are involved in the prevention and treatment of VTE in patients with cancer.

STATEMENT OF NEED
While there may be subtle differences among all the new guidelines for CAT, it is important to understand that these revisions contain substantive changes from preceding versions. The key challenge, however, is that guidelines—even older ones—are not being followed. For example, one missed opportunity for optimizing care is that up to half of patients who should be receiving prophylaxis for VTE are not receiving it, nor are they receiving adequate information from their clinicians, nor are they being involved in decision making with regard to their care, contributing to poor adherence and poor outcomes. Clinicians can benefit substantially from continued education about the importance of CAT prophylaxis, treatment, and available resources to assist with the appropriate care of patients with cancer.

ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation, The International Society on Thrombosis and Haemostasis, and the International Initiative on Thrombosis and Cancer.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation (TFF), The International Society on Thrombosis and Haemostasis (ISTH), and the International Initiative on Thrombosis and Cancer (ITAC). TFF is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians
TFF designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
An application has been made to the UEMS EACCME for CME accreditation of this event.

Nurses
Nurses certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by TFF, an ACCME accredited provider.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, TFF, ISTH, and ITAC require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ISTH, and ITAC resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ISTH, and ITAC seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ISTH, and ITAC are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at TFF, ISTH, and ITAC who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Planners

The faculty listed below report that they have no relevant financial relationships to disclose:

• James D. Douketis, MD, FRCPC, FACP, FCCP, FCAHS
• Dominique Farge-Bancel, MD

The faculty listed below report that they have relevant financial relationships to disclose:

• Jean M. Connors, MD, serves as a consultant for Abbott, Bristol-Myers Squibb, eXlthera, Portola, and Takeda. She receives research funding from CSL Behring

Faculty Disclosures–Activity Faculty
The faculty listed below report that they have no relevant financial relationships to disclose:

• James D. Douketis, MD, FRCPC, FACP, FCCP, FCAHS

DISCLOSURE OF UNLABELED USE
TFF, ISTH, and ITAC require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational. This includes any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ISTH, and ITAC do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grant from BMS/Pfizer Alliance.

DISCLAIMER
TFF, ISTH, and ITAC present this information for educational purposes only. The content is provided solely by faculty who have been selected for their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ISTH, ITAC, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.